Resource Summary Report

Generated by RRID on Jul 31, 2026

Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43

RRID:AB_394284
Type: Antibody

Proper Citation

BD Biosciences Cat# 551892, RRID:AB_394284

Antibody Information

URL: http://antibodyregistry.org/AB_394284

Proper Citation: BD Biosciences Cat# 551892, RRID:AB_394284

Target Antigen: CD279 (PD-1)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43

Description: This monoclonal targets CD279 (PD-1)

Target Organism: mouse

Clone ID: J43

Antibody ID: AB_394284

Vendor: BD Biosciences

Catalog Number: 551892

Record Creation Time: 20250820T052424+0000

Record Last Update: 20250820T212953+0000

Ratings and Alerts

No rating or validation information has been found for Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43.

No alerts have been found for Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. Cell genomics, 4(10), 100659.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. Molecular cell, 84(6), 1120.

Yang C, et al. (2024) Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer cell, 42(12), 2064.

Li X, et al. (2024) Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation. Immunity, 57(7), 1603.

Tesfay MZ, et al. (2024) Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade. Molecular therapy. Oncology, 32(4), 200913.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nature communications, 14(1), 2859.

Dan J, et al. (2023) Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell reports. Medicine, 4(10), 101229.

Ertveldt T, et al. (2023) Targeted ?-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64(5), 751.

Masle-Farquhar E, et al. (2022) STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation. Immunity, 55(12), 2386.

Wan S, et al. (2021) Costimulation molecules differentially regulate the ERK-Zfp831 axis to shape T follicular helper cell differentiation. Immunity, 54(12), 2740.

Sun L, et al. (2021) Transcription factor Ascl2 promotes germinal center B cell responses by directly regulating AID transcription. Cell reports, 35(9), 109188.

Du H, et al. (2019) Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer cell, 35(2), 221.

Shen E, et al. (2019) Control of Germinal Center Localization and Lineage Stability of Follicular Regulatory T Cells by the Blimp1 Transcription Factor. Cell reports, 29(7), 1848.

Ma X, et al. (2019) Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. Cell metabolism, 30(1), 143.

Stutz MD, et al. (2018) Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for Mycobacterium tuberculosis Infection? Frontiers in immunology, 9, 1178.